

Special Issue

Perioperative Interventions and Oncological Outcome in Surgical Cancer Patients

Message from the Guest Editor

Surgery is an important component of treatment for the majority of solid organ tumours. Unfortunately, cancer recurrence following the surgery of curative intent is common, and typically results in refractory disease and patient death. Surgery and other perioperative interventions can induce a biological state conducive to the survival and growth of residual cancer cells released from the primary tumour intra-operatively, which may influence the risk of subsequent metastatic disease. Evidence is accumulating that anaesthetic and analgesic agents could affect many of these pathophysiological processes, influencing risk of cancer recurrence in either a beneficial or detrimental way. This Special Issue brings together the best current, peer-reviewed experimental, and clinical evidence regarding this crucial multidisciplinary research question. The research projects described are the necessary intermediate steps in defining the scientific mechanism underpinning this hypothesis.

Guest Editor

Prof. Dr. Donal J Buggy

1. Department of Anaesthesiology and Perioperative Medicine, Mater University Hospital, School of Medicine, University College Dublin, Ireland
2. EU-COST Action 15204, Euro-Periscope
3. Outcomes Research, Cleveland Clinic, Cleveland, OH, USA

Deadline for manuscript submissions

closed (31 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/32072

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)